Human medicines European public assessment report (EPAR): Flixabi, infliximab, Spondylitis, Ankylosing,Arthritis, Rheumatoid,Crohn Disease,Colitis, Ulcerative,Arthritis, Psoriatic,Psoriasis, Date of authorisation: 26/05/2016, Revision: 10, Status: Authorised